A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Advanced Solid Tumors That Are MTAP Deficient
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 334 (planned)
- Started
- Jan 18, 2024
- Main results expected
- Dec 4, 2028
- Fully finished
- Dec 4, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents
Measured over: From time of informed consent to 28 days post last dose of study treatment
Module 1: Incidence of dose-limiting toxicities (DLT)
Measured over: From first dose of study treatment until the end of Cycle 1 (each cycle is 21 days)
Module 2: Progression Free Survival assessed by the Investigator according to RECIST v1.1
Measured over: From date of randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06130553 · record last updated 2026-08-27 · checked 2026-11-09 15:47 UTC